Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M
Source: SeekingAlpha
2025-03-12 06:53:54 ET
More on Ionis Pharmaceuticals, Ono Pharmaceutical, etc.
- Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript
- Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval
- Ionis Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call Presentation
- Ionis Pharmaceuticals targets multibillion-dollar revenue potential with TRYNGOLZA and new launches
- Ionis posts Q4 beat as revenue base widens
Read the full article on Seeking Alpha
For further details see:
Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M
Ionis Pharmaceuticals Inc.
NASDAQ: IONS
IONS Trading
-2.85% G/L:
$72.635 Last:
681,969 Volume:
$74.30 Open:
IONS Latest News
February 27, 2026 07:00:00 am
Ionis to present new data supporting DAWNZERA(TM) (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
February 26, 2026 07:00:00 am
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
IONS Stock Data
$13,602,609,524
157,763,059
0.53%
186
N/A
Biotechnology & Life Sciences
Healthcare
US
Carlsbad
